European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk (Q52845873)
scientific article published on 27 October 2016
Language:
(P31) (Q13442814)
(P50) (Q38544116)
(Q37841297)
(Q57241500)
(Q27235435)
(Q62560161)
(Q76506012)
(P304) 2245-2255
(P433) 29
(P478) 38
(P577) Thursday, October 27, 2016
(P921) (Q12252367)
(Q11068)
(P1433) (Q2286839)
(P1476) "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk" (language: en)
(P2093) M. John Chapman
Michel Farnier
Baris Gencer
Stephan Gielen
David Sinning
Lale Tokgözoglu
Jose Luis Zamorano
European Society of Cardiology (ESC)
European Atherosclerosis Society (EAS)
(P2860) (Q50116064)
(Q35534337)
(Q28080618)
(Q34046881)
(Q40915596)
(Q36854531)
(Q27027617)
(Q29616310)
(Q28202519)
(Q38636461)
(Q34473809)
(Q34467233)
(Q34043472)
(Q39091664)
(Q40884693)
(Q29617910)
(Q50593957)
(Q39765898)
(Q38712060)
(Q31044439)
(Q34491521)
(Q38082310)
(Q27024882)
(Q34071937)
(Q38618619)
(Q30301147)
(Q41613122)
(Q36973946)
(Q24645376)
(Q35114991)
(Q36076131)
(Q34479098)
(Q39910939)
(Q36278291)
(Q46215056)
(Q29622947)
(Q28083004)
(Q41746611)
(Q34661723)
(Q38209108)
(Q33161987)
(Q45970166)
(Q38394128)
(Q57658223)
(Q58007481)
other details
description scientific article published on 27 October 2016

External Links